Equities

Lyell Immunopharma Inc

LYEL:NSQ

Lyell Immunopharma Inc

Actions
  • Price (USD)0.90
  • Today's Change-0.05 / -5.26%
  • Shares traded3.71m
  • 1 Year change-46.43%
  • Beta-0.4791
Data delayed at least 15 minutes, as of Nov 25 2024 20:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments546640615
Total Receivables, Net------
Total Inventory------
Prepaid expenses8.461111
Other current assets, total------
Total current assets555651626
Property, plant & equipment, net142166167
Goodwill, net------
Intangibles, net------
Long term investments49115331
Note receivable - long term------
Other long term assets4.244.683.48
Total assets7509381,127
LIABILITIES
Accounts payable4.823.923.21
Accrued expenses272628
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total3.076.7116
Total current liabilities353747
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total6167151
Total liabilities95104198
SHAREHOLDERS EQUITY
Common stock0.030.030.02
Additional paid-in capital1,6571,6081,516
Retained earnings (accumulated deficit)(1002)(767)(584)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(0.09)(7.6)(1.62)
Total equity655833930
Total liabilities & shareholders' equity7509381,127
Total common shares outstanding254250243
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.